enGene Therapeutics Inc.

ENGN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001980845

Other share classesENGNW

Price chart

Open-market purchases and sales by ENGN insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Sep 24, 20264:40 PM ETSep 22, 2026Grossman WilliamInterim Chief Medical OfficerPPurchaseCommon Shares+5.1K$1.97+$10.05K5.1KNew positionSEC
Nov 1, 20244:15 PM ETOct 30, 2024Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% OwnerPPurchaseCommon Shares+561.8K$8.90+$5M3.03M+22.7%SEC
Oct 18, 20244:15 PM ETDec 27, 2023 – Oct 8, 2024Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% OwnerPPurchaseCommon Shares+470.63K$6.4013+$3.01M2.47M+23.5%SEC
Oct 1, 2024Sep 27, 2024Cooper Ronald Harold WilfredChief Executive OfficerPPurchaseCommon Shares+10K$5.70+$57K10KNew positionSEC
Apr 22, 2024Apr 18 – Apr 22, 2024FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC10% OwnerSSaleCommon shares−52.53K$15.0009−$787.98K3.04M−1.7%SEC

The largest institutional positions in ENGN at the end of Q2 2026.

Institutions holding ENGN in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FCPM III SERVICES B.V.9,632,561$16.66M2.22%00.0%Unchanged
BML Capital Management, LLC6,669,908$11.54M6.59%+6,669,908New
Siren, L.L.C.6,256,662$10.82M0.22%+1,003,503+19.1%Added
PERCEPTIVE ADVISORS LLC4,822,169$8.34M0.13%−1,005,337−17.3%Reduced
AMERIPRISE FINANCIAL INC2,675,876$4.63M0.00%+2,675,876New